Zykov K A, Tatenkulova S N, Mareev V Iu, Masenko B P, Balakhonova T V, Tripoten' M I, Kaznacheeva E I, Beliavskiĭ E A, Tkachev G A, Belenkov Iu N
Kardiologiia. 2009;49(4):29-36.
To study features of statin therapy in patients with heart failure (HF) of different etiology on immune system.
The basic markers of immune activation in 43 patients with chronic heart disease (CHD) and HF in New York Heart Association (NYHA) class I to IV were studied. Mine age was 48 +/- 8 years (from 33 to 64 years). 43 patients with dilated cardiomyopathy (DCM) and HF were also observed. Mine age was 43 +/- 10 years (from 22 to 61 years). Parameters of systolic and diastolic left ventricle (LV) function were measured. Also non invasive methods for evaluation of endothelial function were used. Concentrations of hsCRP, IgG, IgA, IgM were measured using commercially available kits. IL 6, IL 8, sIL 2R, IL 18, IL 10, IFN Y, endothelin levels were measured using enzyme linked immunosorbent assay method.
Statin therapy has immunomodulation effect in patients with heart failure any etiology. This effect depends on etiology of HF. In CHD patients the decreasing of IFN Y, IL 8, sIL 2R, hsCRP and increasing of IL 18, IL 6 levels were observed. In DCM patients the decreasing of IL 8, IL 18, sIL 2R and increasing of IL 10 were observed. There was significant clinical improving in patients with DCM and HF after statin therapy. But there were no changes of endothelial function in patients with CHD and DCM. There were no changes of LV function in patients with CHD. So statin therapy may reduce level of proinflammatory mediators but not fully control inflammation process in patients with HF of different etiology.
研究不同病因的心力衰竭（HF）患者接受他汀类药物治疗对免疫系统的影响。
对43例纽约心脏协会（NYHA）心功能I至IV级的慢性心脏病（CHD）合并HF患者免疫激活的基本标志物进行了研究。平均年龄为48±8岁（33至64岁）。还观察了43例扩张型心肌病（DCM）合并HF患者。平均年龄为43±10岁（22至61岁）。测量了左心室（LV）收缩和舒张功能参数。还使用了非侵入性方法评估内皮功能。使用市售试剂盒测量hsCRP、IgG、IgA、IgM的浓度。采用酶联免疫吸附测定法测量IL-6、IL-8、sIL-2R、IL-18、IL-10、IFN-γ、内皮素水平。
他汀类药物治疗对任何病因的心力衰竭患者均有免疫调节作用。这种作用取决于HF的病因。在CHD患者中，观察到IFN-γ、IL-8、sIL-2R、hsCRP水平降低，IL-18、IL-6水平升高。在DCM患者中，观察到IL-8、IL-18、sIL-2R水平降低，IL-10水平升高。他汀类药物治疗后，DCM合并HF患者有显著的临床改善。但CHD和DCM患者的内皮功能无变化。CHD患者的LV功能无变化。因此，他汀类药物治疗可能会降低不同病因HF患者的促炎介质水平，但不能完全控制炎症过程。
